Has Dr Paul Cox been named on Neurocept INDs or FDA submissions and how to search FDA records?
This fact-check may be outdated. Consider refreshing it to get the most current information.
Executive summary
Available reporting shows Dr. Paul Alan Cox leads Brain Chemistry Labs and has taken L‑serine research into FDA‑approved human trials, but the sources do not explicitly show his name on Neurocept INDs or other specific FDA submissions (most reporting says he “set up clinical trials” and that FDA approved a Phase II trial) [1] [2] [3]. For how to search FDA records, the FDA’s public FOIA logs and agency webpages are the primary paths to locate submissions, but none of the provided sources list a direct Neurocept filing with his name [4].
1. Who Paul Cox is and what he’s told reporters
Paul Alan Cox is an ethnobotanist and executive director of Brain Chemistry Labs who has been widely profiled for pursuing L‑serine as a possible neuroprotective therapy; Fortune reports his team brought L‑serine into FDA‑approved clinical trials and that the FDA has previously approved L‑serine as a dietary supplement [2]. Multiple organizational profiles and local press pieces repeat that his L‑serine work advanced to at least Phase II clinical trials in collaboration with the Houston Methodist Research Institute [1] [5] [3].
2. What available reporting actually says about FDA filings
The sources say Cox “took the data to the FDA” and “set up clinical trials” and that Brain Chemistry Labs launched “FDA approved Phase II clinical trial” of L‑serine, but none of the provided documents show a specific FDA IND number, an FDA docket entry, or that Cox is named on a Neurocept IND or other formal FDA submission [1] [2] [3]. In short: reporting credits him with initiating FDA‑regulated trials but does not reproduce submission records [1] [2].
3. The difference between press reporting and regulatory records
News stories and organizational bios summarize trial status and collaborations; they are not substitutes for agency filings. Fortune and Brain Chemistry Labs materials describe the research and regulatory progress, yet those sources do not contain the underlying FDA documents or identifiers that would prove who was named on any IND or NDA [2] [6]. Therefore confirming whether Dr. Cox appears by name on a Neurocept IND requires consulting FDA records themselves [2] [6].
4. How to search FDA records (practical, source‑backed steps)
The FDA’s public Freedom of Information Act (FOIA) pages and logs are official starting points for finding records released or requested from the agency; the FOIA Open and Closed Logs list earlier disclosures and can point to documents you can request or download [4]. The FDA also publishes routine “Roundup” and program reports and posts downloadable reports and decision lists that may reference regulatory actions — use those pages to identify reference dates and program areas before filing a targeted FOIA request [7] [8]. Available sources do not mention an FDA search interface specifically for INDs in this result set, so the FOIA logs and agency press/real‑time reports are the documented avenues here [4] [8].
5. If you need confirmation of a named IND or submission
Given the gap between press claims and agency filings in the available materials, request the primary record: submit a FOIA request to the FDA asking for communications, IND submissions, meeting minutes, or correspondence that mention Paul Alan Cox and/or Brain Chemistry Labs in connection with L‑serine or any product name (for example, Neurocept if that is the commercial name you’re tracking). The FDA FOIA page explains how to find and request records; consult the Open/Closed FOIA Logs to see whether related records have already been released [4]. Available sources do not provide a FOIA template or the exact case number for any Cox‑related filing [4].
6. Competing interpretations and hidden agendas
Coverage from Brain Chemistry Labs and profile pieces (Fortune, Good News Network, Garden Club materials) present Cox as the driver of an innovative, patient‑focused research program and emphasize trial progress [2] [3] [5]. Those sources have an interest in promoting the research’s promise; they stop short of publishing FDA submission documents. Independent confirmation via FDA records would eliminate ambiguity. Available sources do not mention any Neurocept IND publicly filed with Cox’s name, nor do they quote FDA documentation showing Cox listed as sponsor or applicant [1] [2] [4].
Limitations: The audit here relies solely on the supplied sources. If you want documentary proof (IND numbers, correspondence, meeting minutes), use the FDA FOIA logs and file a direct FOIA request referencing Paul Alan Cox, Brain Chemistry Labs, L‑serine, and any company names (for example “Neurocept”) you believe may be involved [4]. Available sources do not include those raw FDA records to cite.